605 related articles for article (PubMed ID: 23237131)
21. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Breet NJ; van Werkum JW; Bouman HJ; Kelder JC; Harmsze AM; Hackeng CM; ten Berg JM
Heart; 2011 Jun; 97(12):983-90. PubMed ID: 21478385
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
[TBL] [Abstract][Full Text] [Related]
23. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
Dridi NP; Johansson PI; Clemmensen P; Stissing T; Radu MD; Qayyum A; Pedersen F; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
Platelets; 2014; 25(7):506-12. PubMed ID: 24245960
[TBL] [Abstract][Full Text] [Related]
24. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation.
Park DW; Lee SW; Yun SC; Song HG; Ahn JM; Lee JY; Kim WJ; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
J Am Coll Cardiol; 2011 Dec; 58(25):2630-9. PubMed ID: 22152948
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
[TBL] [Abstract][Full Text] [Related]
26. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
27. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction.
Ahn SG; Lee SH; Yoon JH; Kim WT; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Yoon J; Choe KH
JACC Cardiovasc Interv; 2012 Mar; 5(3):259-67. PubMed ID: 22440490
[TBL] [Abstract][Full Text] [Related]
28. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
[TBL] [Abstract][Full Text] [Related]
29. Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
Olędzki S; Kornacewicz-Jach Z; Safranow K; Kiedrowicz R; Gawrońska-Szklarz B; Jastrzębska M; Gorący J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1085-1094. PubMed ID: 28589365
[TBL] [Abstract][Full Text] [Related]
30. Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction.
Bonello L; Berbis J; Laine M; Armero S; Bessereau J; Jacquin L; Bonello C; Camillieri E; Barragan P; Dignat-George F; Paganelli F; Camoin-Jau L
Thromb Haemost; 2012 Jul; 108(1):101-6. PubMed ID: 22535315
[TBL] [Abstract][Full Text] [Related]
31. Acute coronary syndrome and stable coronary artery disease: are they so different? Long-term outcomes in a contemporary PCI cohort.
Alcock RF; Yong AS; Ng AC; Chow V; Cheruvu C; Aliprandi-Costa B; Lowe HC; Kritharides L; Brieger DB
Int J Cardiol; 2013 Aug; 167(4):1343-6. PubMed ID: 22534045
[TBL] [Abstract][Full Text] [Related]
32. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L
Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430
[TBL] [Abstract][Full Text] [Related]
34. CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.
Kassimis G; Davlouros P; Xanthopoulou I; Stavrou EF; Athanassiadou A; Alexopoulos D
Thromb Res; 2012 Apr; 129(4):441-6. PubMed ID: 21831410
[TBL] [Abstract][Full Text] [Related]
35. Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
Musallam A; Orvin K; Perl L; Mosseri M; Arbel Y; Roguin A; Lev EI
Can J Cardiol; 2016 Oct; 32(10):1246.e13-1246.e19. PubMed ID: 26971236
[TBL] [Abstract][Full Text] [Related]
36. Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study.
Chandrasekhar J; Baber U; Mehran R; Aquino M; Sartori S; Yu J; Kini A; Sharma S; Skurk C; Shlofmitz RA; Witzenbichler B; Dangas G
J Thromb Thrombolysis; 2016 Aug; 42(2):186-96. PubMed ID: 27100112
[TBL] [Abstract][Full Text] [Related]
37. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
[TBL] [Abstract][Full Text] [Related]
38. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
Mangiacapra F; Barbato E; Patti G; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Wijns W; Di Sciascio G
JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992
[TBL] [Abstract][Full Text] [Related]
39. High platelet reactivity is associated with vascular function in patients after percutaneous coronary intervention receiving clopidogrel.
Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Vavuranakis M; Maniatis K; Kokkou E; Papageorgiou N; Papaioannou S; Tourikis P; Papavassiliou AG; Stefanadis C; Tousoulis D
Int J Cardiol; 2014 Nov; 177(1):192-6. PubMed ID: 25499376
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial).
Patti G; Pasceri V; Mangiacapra F; Colonna G; Vizzi V; Ricottini E; Montinaro A; D'Ambrosio A; Wijns W; Barbato E; Di Sciascio G;
Am J Cardiol; 2013 Jul; 112(2):162-8. PubMed ID: 23601577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
